뒤로
Curative Biotechnology Inc (CUBT) 수입
CUBT 주가 차트
CUBT 수입
Curative Biotechnology Inc
$1.1
2.32%
$0.02
오늘 기준:Apr 01, 13:11:26 GMT-4
Earnings FAQ
CUBT의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Curative Biotechnology Inc CUBT의 지난 분기 매출 실적은 어땠나요?
Curative Biotechnology Inc의 매출 추정치는 얼마인가요?
Curative Biotechnology Inc의 수익 품질 점수는 얼마인가요?
Curative Biotechnology Inc는 언제 수익을 보고하나요?
Curative Biotechnology Inc의 예상 수익은 얼마인가요?
Curative Biotechnology Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$1.07
시가
$1.15
일일 범위
$1.05 - $1.2
52주 범위
$0.003 - $1.49
거래량
7.3K
평균 거래량
246.2K
배당수익률
--
EPS(TTM)
-0.01
시가총액
$1.1B
CUBT란 무엇인가요?
Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2001-07-11. The firm is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. The company has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The company is primarily focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its development pipeline is focused on three therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. IMT504 is an oligodeoxynucleotide (ODN). ODNs are synthetic molecules that stimulate different kinds of cells of immune system of animals and humans.